Trial · NCT07301034
A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
NCT07301034, Phase 3, Recruiting, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack. Trials, record NCT07301034. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07301034
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Research Study to Look at the Effect of Ziltivekimab on Plaque in the Blood Vessels of the Heart, Compared to Placebo, in People With a Heart Attack
- NCT number
- NCT07301034
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 332 participants, estimated
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Myocardial Infarction
- Interventions
- Ziltivekimab, Ziltivekimab Placebo
- First posted
- 2025-12-24
- Last updated
- 2026-03-11
Source ClinicalTrials.gov
Registered outcomes18
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interest | From randomisation (week 0) to end-of-study (52-week) | Percentage (%). |
| Secondary | Change in maximum lipid core burden index (LCBI) in any 4-mm segment(maxLCBI4mm) as determined by Near-infrared spectroscopy (NIRS) in matched regions of interest | From randomisation (week 0) to end-of-study (52-week) | Lipid core burden index (LCBI) (0 to 1000). |
| Secondary | Change in minimal fibrous cap thickness as determined by (optical coherence tomography) OCT in matched regions of interest | From randomisation (week 0) to end-of-study (52-week) | Micro meter (µmeter). |
| Secondary | Change in lipid core burden index (LCBI) total as determined by NIRS in matched regions of interest | From randomisation (week 0) to end-of-study (52-week) | LCBI index (0 to 1000). |
| Secondary | Change in average angular extension (AAE) of macrophages as determined by OCT in matched regions of interest | From randomisation (week 0) to end-of-study (52-week) | Degrees (°). |
| Secondary | Change in normalized total atheroma volume (NTAV) by IVUS in matched regions of interest | From randomisation (week 0) to end-of-study (52-week) | Cubic Millimeter (mm3). |
| Secondary | Change in mean fibrous cap thickness as determined by OCT in matched region of interest | From randomisation (week 0) to end-of-study (52-week) | µmeter. |
| Secondary | Change in interleukin6 (IL-6) | From randomisation (week 0) to week 4, and week 52 | Picograms per milliliter (pg/mL). |
| Secondary | Change in high-sensitivity C-reactive protein (hs-CRP) | From randomisation (week 0) to week 4, and week 52 | Milligrams per deciliter (mg/dL). |
| Secondary | Change in high-sensitivity Troponin T (hs-TnT) | From randomisation (week 0) to week 4, and week 52 | Nanograms per milliliter (ng/mL). |
1 to 10 of 18Source ClinicalTrials.gov
See all 18 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07301034
GET https://conductscience.org/api/trials/v1/NCT07301034/registered